| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Fab-12variantY0317, RhuFab |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Ranibizumab (HB941016) is a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | Fab-G1, kappa |
| Target | Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A |
| Purification | Protein L purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P15692 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969
